Inclusion Criteria:

          -  Participants with advanced solid tumors, for whom no standard of care therapy exists
             or for whom is not considered sufficiently effective, or who cannot tolerate standard
             of care

          -  Participants with Eastern Cooperative Oncology Group Performance status 0 or 1

          -  Adequate hematological, hepatic, and renal function as defined in the protocol

          -  Participants in Part 1B (the preliminary food effect assessment) must agree to provide
             paired tumor biopsies if not contraindicated for medical reasons

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Clinically significant (i.e., active) uncontrolled intercurrent illness including, but
             not limited to:

               1. Active infection (i.e., requiring systemic antibiotics or antifungals)

               2. Uncontrolled arterial hypertension

               3. Severe cardiac arrhythmia requiring medication

               4. Cerebral vascular accident/stroke

          -  Has known ataxia telangiectasia

          -  Participants with tumors harboring previously identified ATM mutations

          -  Participants with hypersensitivity to the active substance or to any of the excipients
             of M4076

          -  Other protocol defined exclusion criteria could apply